Behbahani Ali 4

What Happened
Behbahani Ali, a director of CRISPR Therapeutics AG (CRSP), received a derivative award of 13,000 shares (reported as a grant) on June 5, 2026. The filing shows an acquisition price of $0.00 and a reported value of $0, indicating this was a stock-based compensation award (options) rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-05; Form 4 filed: 2026-06-09 (timely under SEC rules).
• Award: 13,000 derivative shares (options) reported at $0.00; total reported value $0.
• Shares owned after transaction: not specified in the provided data.
• Footnote: Options vest and become exercisable in 12 equal monthly installments, with the first vesting on June 30, 2026, and the final installment vesting on the earlier of (i) the one‑year anniversary of the grant or (ii) the date of the 2027 Annual Meeting.
• Transaction code: A (award/grant). No 10b5-1 plan, tax withholding, or late-filing flags noted in the provided information.

Context
This was a compensation grant of options that will vest monthly over up to one year. Until vested and exercised, these derivative awards cannot be sold and do not represent immediate insider purchases or sales. Such grants are routine for directors and reflect compensation; they do not by themselves indicate buying or selling sentiment.